secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2024-05-23T23:59:59+00:00
Accession:  0000950170-24-064022
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel reports Phase 2 CAN-2409 data: 20.6-month median OS in NSCLC patients with ICI resistance
--------------------------------------------------------------------------------

- Median overall survival of 20.6 months in NSCLC patients with progressive disease despite ICI, vs 11.6 months historical SoC docetaxel.
- mOS of 22.0 months across all 46 patients with inadequate ICI response.
- 71.4% of evaluable metastatic patients had beneficial effect on both injected and uninjected tumors (abscopal response).
- Increased circulating CD8+ and CD4+ memory T cells after second injection correlated with prolonged survival.
- Favorable safety: no grade 4+ TRAEs; three grade 3 events (1 pyrexia, 2 pneumonitis).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024064022/0000950170-24-064022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024064022/cadl-20240523.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-064022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer